Evidence map›Paper›PMID 35947676›Full record

ArticleScience translational medicine2022

Differentiation of crescent-forming kidney progenitor cells into podocytes attenuates severe glomerulonephritis in mice.

Maria Elena Melica, Giulia Antonelli, Roberto Semeraro, Maria Lucia Angelotti, Gianmarco Lugli, Samuela Landini, Fiammetta Ravaglia, Gilda La Regina, Carolina Conte, Letizia De Chiara and 16 more

Open access · greenAbstract read
In one paragraph

Article in Science translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 48 citations in OpenAlex.

  1. Cell-cell crosstalk in kidney health and disease.Nature reviews. Nephrology · 2026
    Review
  2. Podocyte Metabolic Reprogramming and Targeted Therapy.Journal of the American Society of Nephrology : JASN · 2026
    Review
  3. Review
  4. Review
  5. Podocytopathies.Nature reviews. Disease primers · 2025
    Review
  6. Cellular senescence in kidney diseases.Chinese medical journal · 2025
    Review
  7. Article
  8. Review
  9. Piezo1, F-Actin Remodeling, and Podocyte Survival and Regeneration.Journal of the American Society of Nephrology : JASN · 2025
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 5 institutions in 3 countries.

Maria Elena MelicaExcellence Center for Research, Transfer and High Education for the Development of DE NOVO Therapies (DENOTHE), University of Florence, Florence 50139, Italy.ORCID 0000-0002-4599-4083
Giulia AntonelliExcellence Center for Research, Transfer and High Education for the Development of DE NOVO Therapies (DENOTHE), University of Florence, Florence 50139, Italy.ORCID 0000-0002-2555-2130
Roberto SemeraroDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Maria Lucia AngelottiExcellence Center for Research, Transfer and High Education for the Development of DE NOVO Therapies (DENOTHE), University of Florence, Florence 50139, Italy.ORCID 0000-0003-3988-7852
Gianmarco LugliDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence 50139, Italy.ORCID 0000-0001-6626-3258
Samuela LandiniNephrology and Dialysis Unit, Meyer Children's Hospital, Florence 50139, Italy.ORCID 0000-0001-7423-0325
Fiammetta RavagliaDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence 50139, Italy.ORCID 0000-0001-7121-2324
Gilda La ReginaDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence 50139, Italy.ORCID 0000-0002-3482-9488
Carolina ConteExcellence Center for Research, Transfer and High Education for the Development of DE NOVO Therapies (DENOTHE), University of Florence, Florence 50139, Italy.ORCID 0000-0002-7679-2935
Letizia De ChiaraExcellence Center for Research, Transfer and High Education for the Development of DE NOVO Therapies (DENOTHE), University of Florence, Florence 50139, Italy.ORCID 0000-0002-8548-2031
Anna Julie PeiredExcellence Center for Research, Transfer and High Education for the Development of DE NOVO Therapies (DENOTHE), University of Florence, Florence 50139, Italy.ORCID 0000-0001-9732-1369
Benedetta MazzinghiNephrology and Dialysis Unit, Meyer Children's Hospital, Florence 50139, Italy.ORCID 0000-0003-2809-5622
Marta DonatiNephrology and Dialysis Unit, Meyer Children's Hospital, Florence 50139, Italy.
Alice MolliNephrology and Dialysis Unit, Meyer Children's Hospital, Florence 50139, Italy.
Stefanie SteigerDivision of Nephrology, Medizinische Klinik and Poliklinik IV, Klinikum der LMU München, Munich 80336, Germany.ORCID 0000-0002-5990-494X
Alberto MagiDepartment of Information Engineering, University of Florence, Florence, Italy.ORCID 0000-0001-7393-4283
Niccolò BartalucciDepartment of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, AOUC, University of Florence, Florence 50139, Italy.ORCID 0000-0002-9328-3948
Valentina RagliantiDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence 50139, Italy.
Francesco GuzziDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence 50139, Italy.ORCID 0000-0003-0788-5078
Laura MaggiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Francesco AnnunziatoDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Alexa BurgerSection of Developmental Biology, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0001-7137-3910
Elena LazzeriExcellence Center for Research, Transfer and High Education for the Development of DE NOVO Therapies (DENOTHE), University of Florence, Florence 50139, Italy.ORCID 0000-0002-9505-2115
Hans-Joachim AndersDivision of Nephrology, Medizinische Klinik and Poliklinik IV, Klinikum der LMU München, Munich 80336, Germany.ORCID 0000-0003-2434-2956
Laura LasagniExcellence Center for Research, Transfer and High Education for the Development of DE NOVO Therapies (DENOTHE), University of Florence, Florence 50139, Italy.ORCID 0000-0001-6553-9160
Paola RomagnaniExcellence Center for Research, Transfer and High Education for the Development of DE NOVO Therapies (DENOTHE), University of Florence, Florence 50139, Italy.ORCID 0000-0002-1774-8088
European Society for Sexual Medicine · ITUniversity of Florence · ITMeyer Children's Hospital · ITLMU Klinikum · DEUniversity of Colorado Anschutz Medical Campus · US

Funding

European Research Council 101019891
6 · The paper itself

Abstract

Crescentic glomerulonephritis is characterized by vascular necrosis and parietal epithelial cell hyperplasia in the space surrounding the glomerulus, resulting in the formation of crescents. Little is known about the molecular mechanisms driving this process. Inducing crescentic glomerulonephritis in two Pax2Cre reporter mouse models revealed that crescents derive from clonal expansion of single immature parietal epithelial cells. Preemptive and delayed histone deacetylase inhibition with panobinostat, a drug used to treat hematopoietic stem cell disorders, attenuated crescentic glomerulonephritis with recovery of kidney function in the two mouse models. Three-dimensional confocal microscopy and stimulated emission depletion superresolution imaging of mouse glomeruli showed that, in addition to exerting an anti-inflammatory and immunosuppressive effect, panobinostat induced differentiation of an immature hyperplastic parietal epithelial cell subset into podocytes, thereby restoring the glomerular filtration barrier. Single-cell RNA sequencing of human renal progenitor cells in vitro identified an immature stratifin-positive cell subset and revealed that expansion of this stratifin-expressing progenitor cell subset was associated with a poor outcome in human crescentic glomerulonephritis. Treatment of human parietal epithelial cells in vitro with panobinostat attenuated stratifin expression in renal progenitor cells, reduced their proliferation, and promoted their differentiation into podocytes. These results offer mechanistic insights into the formation of glomerular crescents and demonstrate that selective targeting of renal progenitor cells can attenuate crescent formation and the deterioration of kidney function in crescentic glomerulonephritis in mice.

Indexed as

GlomerulonephritisPodocytesAnimalsDisease Models, AnimalHumansKidneyMicePanobinostatStem CellsPanobinostat

Identifiers

PMID35947676
PMCPMC7614034
OpenAlexW4291020786

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.